首页> 外文OA文献 >Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors

【2h】

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors

机译：连续日期HSP90抑制剂给药改善了试剂术恶性肿瘤和犬肥大细胞肿瘤的鼠模型的疗效

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Cheryl A. London; Jaime Acquaviva; Donald L. Smith; Manuel Sequeira; Luisa Shin Ogawa; Heather L. Gardner; Louis Feo Bernabe; Misty D. Bear; Sandra A. Bechtel; David A. Proia;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors [J] . London Cheryl A., Acquaviva Jaime, Smith Donald L., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第24期

机译：连续日期HSP90抑制剂给药改善了试剂术恶性肿瘤和犬肥大细胞肿瘤的鼠模型的疗效
2. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice [J] . E Ikebe, A Kawaguchi, K Tezuka, Blood cancer journal. . 2013,第8期

机译：口服HSP90抑制剂17-DMAG可干预肿瘤细胞向多个器官的浸润并改善ATL模型小鼠的生存期
3. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors [J] . Khanh Do, Giovanna Speranza, Lun-Ching Chang, Investigational New Drugs . 2015,第4期

机译：I期研究热休克蛋白90（Hsp90）抑制剂onalespib（AT13387）在患有晚期实体瘤的患者中每天连续2天每天给药一次
4. Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors [C] . American College of Veterinary Internal Medicine Forum Conference . 2019

机译：对腹腔内Tigilanol Tiglate（EBC-46）的控制，随机研究用于治疗犬肥大细胞瘤
5. Understanding How Adrenergic Stress Signaling Impacts the Anti-Tumor Immune Response and the Efficacy of Checkpoint Inhibitors in Murine Tumor Models [D] . Bucsek, Mark Joseph. 2019

机译：了解肾上腺素能应激信号如何影响抗肿瘤免疫应答以及检查点抑制剂在鼠肿瘤模型中的疗效
6. Consecutive day HSP90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors [O] . Cheryl A. London, Jaime Acquaviva, Donald L. Smith, -1

机译：连续一天使用HSP90抑制剂可改善在KIT驱动的恶性肿瘤和犬肥大细胞肿瘤的小鼠模型中的功效
7. Oral administration of an HSP90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice [O] . Ikebe Emi, Kawaguchi Akira, Tezuka K, 2013

机译：口服Hsp90抑制剂17-DmaG介入肿瘤细胞浸润到多个器官并改善aTL模型小鼠的存活期

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors

著录项

引文网络

相似文献

相关主题

期刊订阅